{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:07:38Z","timestamp":1784977658528,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.04.018","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T03:02:45Z","timestamp":1745982165000},"page":"819-828.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Rupal","family":"O\u2019Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Corry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmana","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Jannuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.04.018_bib0001","first-page":"81","article-title":"Use of BTK inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a practical guidance","volume":"12","author":"St-Pierre","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.04.018_bib0002","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.clml.2025.04.018_bib0003","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncology"},{"issue":"24","key":"10.1016\/j.clml.2025.04.018_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10245845","article-title":"Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: a real life experience","volume":"10","author":"Broccoli","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2025.04.018_bib0005","series-title":"Imbruvica [package insert]","year":"2023"},{"issue":"1","key":"10.1016\/j.clml.2025.04.018_bib0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.122.001116","article-title":"Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent Bruton tyrosine kinase inhibitors","volume":"384","author":"Podoll","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2025.04.018_bib0007","series-title":"Calquence [package insert]","year":"2022"},{"issue":"31","key":"10.1016\/j.clml.2025.04.018_bib0008","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.04.018_bib0009","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.clml.2025.04.018_bib0010","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.018_bib0011","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.clml.2025.04.018_bib0012","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.clml.2025.04.018_bib0013","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/bjh.16859","article-title":"High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study","volume":"190","author":"Larsson","year":"2020","journal-title":"Br J Haematol"},{"issue":"10232","key":"10.1016\/j.clml.2025.04.018_bib0014","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clml.2025.04.018_bib0015","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.04.018_bib0016","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"41","key":"10.1016\/j.clml.2025.04.018_bib0017","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.clml.2025.04.018_bib0018","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.clml.2025.04.018_bib0019","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.clml.2025.04.018_bib0020","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.018_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clml.2025.04.018_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133134","article-title":"Chemoimmunotherapy in the first-line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking?","volume":"13","author":"Smolej","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.04.018_bib0023","series-title":"Bendeka [package insert]","year":"2024"},{"key":"10.1016\/j.clml.2025.04.018_bib0024","series-title":"Rituxan [package insert]","year":"2021"},{"key":"10.1016\/j.clml.2025.04.018_bib0025","unstructured":"FDA Grants Accelerated Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic#:~:text=On%20December%201%2C%202023%2C%20the%20Food%20and,lines%20of%20therapy%2C%20including%20a%20BTK%20inhibitor. Accessed: 11 January 2024."},{"issue":"1","key":"10.1016\/j.clml.2025.04.018_bib0026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:39:23Z","timestamp":1776397163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025001508"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}